Overall, our study confirmed that MYO1G promoter methylation and gene expression were predictive biomarkers for immune cell infiltration in the tumor microenvironment, prognosis and immunotherapy response of cutaneous melanoma patients. This evidence concerns the gene MYO1G and neoplasm.